iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

AIM: For people with suboptimally controlled type 2 diabetes (T2D) on basal insulin (BI), guidelines recommend several treatment advancement options. This study compared the clinical effectiveness of once‐daily iGlarLixi versus a multiple‐injection BI + rapid acting insulin (RAI) regimen in adults w...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrimmon, Rory J., Cheng, Alice Y.Y., Galstyan, Gagik, Djaballah, Khier, Li, Xuan, Coudert, Mathieu, Frias, Juan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087837/
https://www.ncbi.nlm.nih.gov/pubmed/36123617
http://dx.doi.org/10.1111/dom.14844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087837/
https://www.ncbi.nlm.nih.gov/pubmed/36123617
http://dx.doi.org/10.1111/dom.14844

Ejemplares similares